NCT00870727View on ClinicalTrials.gov

Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions
Pervasive Developmental Disorder
Interventions
DRUG

Aripiprazole oral product

Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.

DRUG

Placebo oral capsule

Placebo will be identical in size and appearance to study drug.

Trial Locations (1)

46202

Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Indiana University

OTHER